Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$1.36 -3.5%	$1.33	$0.86 ▼ $3.36	$85.41M	0.14	255,601 shs	74,438 shs
ANRO Alto Neuroscience	$3.59 +4.7%	$2.77	$1.60 ▼ $15.04	$92.87M	1.84	102,550 shs	122,565 shs
ATRA Atara Biotherapeutics	$11.49 -2.3%	$10.03	$5.01 ▼ $18.70	$82.59M	0.26	53,787 shs	31,143 shs
ELEV Elevation Oncology	$0.37	$0.37	$0.22 ▼ $3.09	$21.62M	1.48	1.18 million shs	N/A

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	-3.55%	-2.86%	-18.56%	+33.33%	-52.28%
ANRO Alto Neuroscience	+4.39%	+15.14%	+26.63%	+17.55%	-67.51%
ATRA Atara Biotherapeutics	-2.30%	-1.96%	-11.75%	+60.92%	+58.48%
ELEV Elevation Oncology	0.00%	0.00%	0.00%	+15.62%	-54.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABOS Acumen Pharmaceuticals	3.04 of 5 stars	3.5	5.0	0.0	1.4	1.7	0.6
ANRO Alto Neuroscience	1.7499 of 5 stars	3.3	1.0	0.0	1.1	0.8	1.3
ATRA Atara Biotherapeutics	4.6444 of 5 stars	3.4	4.0	4.7	3.1	3.3	0.6
ELEV Elevation Oncology	1.3858 of 5 stars	3.0	0.0	0.0	0.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABOS Acumen Pharmaceuticals	3.00	Buy	$6.33	365.69% Upside
ANRO Alto Neuroscience	2.57	Moderate Buy	$8.50	136.77% Upside
ATRA Atara Biotherapeutics	2.80	Moderate Buy	$21.00	82.77% Upside
ELEV Elevation Oncology	2.00	Hold	$2.62	616.89% Upside

Current Analyst Ratings Breakdown

Latest ELEV, ATRA, ABOS, and ANRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/26/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/17/2025	ABOS Acumen Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
6/10/2025	ELEV Elevation Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/10/2025	ELEV Elevation Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral
6/9/2025	ELEV Elevation Oncology	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/9/2025	ELEV Elevation Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	$1.93 per share	N/A
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$4.56 per share	N/A
ATRA Atara Biotherapeutics	$128.94M	0.63	N/A	N/A	($4.99) per share	-2.30
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	$1.02 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABOS Acumen Pharmaceuticals	-$102.33M	-$2.28	N/A	N/A	N/A	N/A	-81.39%	-61.96%	N/A
ANRO Alto Neuroscience	-$61.43M	-$2.39	N/A	N/A	N/A	N/A	-44.34%	-36.73%	N/A
ATRA Atara Biotherapeutics	-$85.40M	-$0.43	N/A	N/A	N/A	3.07%	-8.34%	6.61%	N/A
ELEV Elevation Oncology	-$44.49M	-$0.82	N/A	N/A	N/A	N/A	-74.68%	-48.14%	11/4/2025 (Estimated)

Latest ELEV, ATRA, ABOS, and ANRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ANRO Alto Neuroscience	-$0.57	-$0.65	-$0.08	-$0.65	N/A	N/A
8/12/2025	Q2 2025	ABOS Acumen Pharmaceuticals	-$0.54	-$0.68	-$0.14	-$0.68	N/A	N/A
8/11/2025	Q2 2025	ATRA Atara Biotherapeutics	-$0.32	$0.19	+$0.51	$0.19	$4.23 million	$17.58 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABOS Acumen Pharmaceuticals	0.26	5.97	5.97
ANRO Alto Neuroscience	0.18	18.43	18.43
ATRA Atara Biotherapeutics	N/A	1.70	1.70
ELEV Elevation Oncology	0.67	19.40	19.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABOS Acumen Pharmaceuticals	71.01%
ANRO Alto Neuroscience	N/A
ATRA Atara Biotherapeutics	70.90%
ELEV Elevation Oncology	83.70%

Insider Ownership

Company	Insider Ownership
ABOS Acumen Pharmaceuticals	9.30%
ANRO Alto Neuroscience	11.13%
ATRA Atara Biotherapeutics	4.00%
ELEV Elevation Oncology	8.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABOS Acumen Pharmaceuticals	20	60.57 million	54.94 million	Optionable
ANRO Alto Neuroscience	N/A	27.08 million	24.06 million	N/A
ATRA Atara Biotherapeutics	330	7.02 million	6.74 million	Optionable
ELEV Elevation Oncology	40	59.22 million	54.43 million	Optionable

ELEV, ATRA, ABOS, and ANRO Headlines

Recent News About These Companies

Brokerages Set Elevation Oncology, Inc. (NASDAQ:ELEV) Target Price at $2.62

August 19 at 2:17 AM | americanbankingnews.com

Tang Capital’s Concentra on Buyout Binge With Plenty of Biotech Fodder

August 13, 2025 | biospace.comB

Elevation Oncology Terminates License Agreement with CSPC

July 25, 2025 | theglobeandmail.com

Elevation Oncology Completes Merger with Concentra Biosciences

July 23, 2025 | tipranks.com

Serial acquirer Concentra Biosciences on a buyout spree in 2025

July 15, 2025 | labiotech.euL

ELEV - Elevation Oncology Inc Sustainability | Morningstar

July 11, 2025 | morningstar.comM

Concentra throws lifeline to troubled CARGO Therapeutics

July 9, 2025 | pharmaphorum.comP

Why 'emboldened' activist investors are taking the fight to biotechs

July 2, 2025 | fiercebiotech.comF

HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Elevation Oncology, Inc. (NASDAQ: ELEV)

June 15, 2025 | globenewswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders

June 12, 2025 | prnewswire.com

ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation ...

June 12, 2025 | morningstar.comM

HC Wainwright & Co. Downgrades Elevation Oncology (ELEV)

June 12, 2025 | msn.com

Concentra buys out another struggling Boston biotech

June 11, 2025 | bizjournals.com

ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc. - ELEV

June 10, 2025 | businesswire.com

Elevation Oncology agrees to be acquired by Concentra

June 10, 2025 | thepharmaletter.comT

Elevation Oncology stock soars on Concentra merger agreement

June 10, 2025 | au.investing.com

Concentra Biosciences to Buy Out Elevation Oncology After Pipeline Reshuffle

June 10, 2025 | precisionmedicineonline.comP

Elevation Oncology to Be Acquired by Concentra Biosciences

June 10, 2025 | marketwatch.com

Concentra to acquire Elevation in bid to eliminate another biotech ‘zombie’

June 10, 2025 | finance.yahoo.com

Embattled Elevation becomes latest biotech to accept Concentra buyout offer

June 10, 2025 | fiercebiotech.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ELEV, ATRA, ABOS, and ANRO Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

$1.36 -0.05 (-3.55%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$1.38 +0.02 (+1.84%)

As of 08/21/2025 07:34 PM Eastern

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Alto Neuroscience NYSE:ANRO

$3.59 +0.16 (+4.66%)

Closing price 08/21/2025 03:59 PM Eastern

Extended Trading

$3.49 -0.10 (-2.79%)

As of 08/21/2025 07:28 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Atara Biotherapeutics NASDAQ:ATRA

$11.49 -0.27 (-2.30%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$11.64 +0.15 (+1.35%)

As of 08/21/2025 04:43 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Elevation Oncology NASDAQ:ELEV

$0.36 0.00 (0.00%)

As of 07/23/2025

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time